Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Improves Endothelial Dysfunction in Association With Its Anti-Inflammatory Effects in Patients With Coronary Artery Disease and Uncontrolled Diabetes

Junichi Matsubara(Kumamoto University Hospital), Hisao Ogawa(Jikei University School of Medicine), Eiichiro Yamamoto(Kumamoto University), Seiji Hokimoto(Omuta hospital), Seigo Sugiyama(Kumamoto University), Koichi Kaikita(Kumamoto University), Koichiro Fujisue(Kumamoto University), Hirofumi Maeda(Kumamoto University), Hideaki Jinnouchi(Kumamoto University Hospital), Satomi Iwashita(Kumamoto University), Eiichi Akiyama(Kumamoto University), Hirofumi Kurokawa(Kumamoto University), Keisuke Ohba(Kumamoto University)
Circulation Journal
January 1, 2013
10.1253/circj.cj-12-1168
Cited by 199

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449